- Zacks Small Cap Research•4 hours ago
MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 was previously tested in a randomized, double blind, placebo controlled Phase 2a clinical trial to evaluate its safety and effectiveness in relapsing MS patients.
- Associated Press•yesterday
On a per-share basis, the La Jolla, California-based company said it had a loss of 8 cents. MediciNova shares have risen 100 percent since the beginning of the year. The stock has more than doubled in ...
- GlobeNewswire•16 days agoMediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Oct. 11, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the U.S. Food ...
MediciNova Inc. (MNOV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||7.10 x 200|
|Ask||7.11 x 200|
|Day's Range||7.09 - 7.20|
|52wk Range||2.74 - 10.16|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-19.45|
|Avg Vol (3m)||49,390|
|Dividend & Yield||N/A (N/A)|